FDA requests additional trial for Ampio's osteoarthritis therapy Ampion

Ampio Pharmaceuticals Inc. (NYSE-M:AMPE) said FDA requested an additional randomized trial of Ampion to treat severe osteoarthritis (OA) of the knee prior

Read the full 220 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE